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shows synovial fluid CS content of the 3 groups as determined
by DMMB. For comparison, Figure 1B shows total sulfated chon-
droitin disaccharide (delta di6S and delta di4S) for the same
samples determined by FACE. For both methods, CS peak oc-
curs at fraction 18 in synovial fluid from joints with OC injury.
Similarly, CS in synovial fluid from exercised joints peaks in frac-
tion 19 with both assays. CS in synovial fluid from rested joints
peaks in fraction 19 when determined by DMMB, but peaks in
fraction 20 when measured by FACE. When ug/ml amounts of
CS for each data point were compared between assays, results
for exercised (n=80) and OC injury joints (n=70) were signifi-
cantly different (P<0.0001), but results for rested joints (n=80)
were not (P=0.92).
Conclusions: When used for quantitation of sulfated CS in syn-
ovial fluid (ug/ml), DMMB gave results that were significantly
different than those from FACE. DMMB may be measuring other
sGAGs in addition to CS. However, when performed after Su-
perose 6 chromatography, DMMB assay appears to discriminate
the longer CS chains in synovial fluid from OC injured joints from
the shorter chains seen in normal joints. Thus, for the specific
purposes of determination of CS chain length, the more simple,
less expensive DMMB assay may be a replacement for FACE
assay. Use of a 384-well microplate allowed use of low volumes
of DMMB reagents. This facilitated quantitation of small amounts
of CS in fractions collected from Superose 6 chromatography.
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Purpose: Adipocytokines resistin and adiponectin are the major
members of adipose tissue-derived peptides, which have been
suggested as a link between insulin resistance, diabetes, and
obesity. Recent data provided also body of evidence on the
implication of adipocytokines in the inflammation, immune re-
sponse, and tissue destruction. This study was undertaken to
examine the (patho)physiological role of resistin and adiponectin
in matched serum and synovial fluid samples from patients with
rheumatoid arthritis (RA) and osteoarthritis (OA).
Methods: Blood and synovial fluid samples from 20 RA and 20
OA patients were analyzed for resistin and adiponectin (ELISA,
Biovendor). The clinical activity of patients with OA and RA
was assessed according to the Western Ontario and McMaster
Universities (WOMAC) index and the 28 joint count Disease
Activity Score (DAS28), respectively.
Results: Serum resistin levels were significantly lower in OA
compared to RA patients (p=0.002), however the levels of
adiponectin in those patients were comparable (p=0.38).
The levels of both adipocytokines in synovial fluid were signifi-
cantly lower in OA than in RA patients (p<0.001). Adiponectin
concentration was lower in synovial fuid than that in systemic
circulation in both diseases. However, in contrast to OA patients,
resistin levels were significantly higher in synovial fluid than in
systemic circulation in RA patients. In RA patients, increased
serum resistin correlated positively with CRP (r=0.53, p<0.02)
and DAS28 (r=0.44, p<0.05), and adiponectin correlated nega-
tively with leukocyte count in synovial fluid (r= -0.45, p<0.05).
No such correlation was observed in OA patients.
Conclusions: The local up-regulation of adipocytokines in RA
synovial fluid points to a possible role of these molecules in
the pathophysiology of inflammatory joint diseases such as RA
rather than OA.
Acknowledgement: this study was supported by the Czech
Ministry of Health (research project 00023728 and 64165).
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Purpose: Aggrecan is the major proteoglycan in articular carti-
lage, and is degraded and released from the extracellular matrix
in pathological joint debilitating diseases like osteoarthritis (OA).
The aggrecanases, ADAMTS-4 and ADAMTS-5, and an array
of Matrix Metallo Proteinases (MMPs) are up-regulated in os-
teoarthritis (OA). The aim of the current study was to monitor the
aggrecanase and MMP mediated turnover of aggrecan in human
OA cartilage in response to different cytokines.
Methods: Articular cartilage was obtained from OA patients,
who had undergone total knee arthroplasty. Articular cartilage
was cultured for 21 days with refreshment of medium every 3rd
day in the presence of 100 ng/mL Interleukin-1 alpha (IL-1α)
or 10 ng/ml Oncostatin M (OSM) + 20 ng/mL Tumour Necro-
sis Factor alpha (OSM/TNFα) to stimulate cartilage degradation.
As negative control, explants without cytokine stimulation were
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used. Cartilage degradation was monitored by measuring the
conditioned medium in 4 independent assays (1) 342-G2 assay,
composed of the capturing antibody AF-28 against the 342FFGVG
neo-epitope generated by MMP-cleavage and the monoclonal
antibody F-78 binding to both the Globular 1 (G1) and Globu-
lar 2 (G2) domain of aggrecan; (2) 374-G2 assay, made up by
the capturing antibody BC-3 against the 374ARGSVI neo-epitope
created by ADAMTs cleavage and F-78; (3) MMP mediated colla-
gen type II degradation (CTX-II) quantified by ELISA; (4) release
of total glycosaminoglycans (GAGs). Furthermore, immunohisto-
chemistry was performed with the monoclonal antibodies AF-28
and BC-3 on OA cartilage to localize the epitopes.
Results: OSM/TNFα caused a significant release of aggre-
canase mediated 374-G2 containing molecules in the early (day
4-9), mid (day 10-15) and late phase (day 16-21) and GAGs in
the early and mid phase compared to non-stimulated explants
(1000 fold increase of 374-G2 at day 14). On the other hand,
stimulation with IL-1α resulted in a release of aggrecanase me-
diated 374-G2 antigens and GAGs in the mid and late phase
when compared to non-stimulated explants (50 fold increase of
374-G2 at day 14). No remarkable release of MMP mediated
CTX-II or 342-G2 analytes were detected with OSM/TNFα or IL-
1α throughout the whole period. Immunohistochemistry showed
an intense staining with BC-3 in the calcified cartilage zone and
in the articular surface, where erosion had occurred.
Conclusions: In the present study, we have shown that stim-
ulation of ex vivo human explant cultures with OSM/TNFα or
IL-1α results in release of aggrecanase mediated 374-G2 an-
alytes, but not MMP mediated 342-G2 molecules. By careful
assessment of biochemical markers, these provide information
on which proteases are activated, when stimulating explants with
pro-inflammatory cytokines. We suggest that these assays are
valuable diagnostic tools for assessing the turnover of aggre-
can in human arthritis, which may aid in understanding disease
mechanisms leading to pathologies such as OA.
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Purpose: Osteoarthritis (OA) is usually used as a control for
rheumatoid arthritis (RA) when measuring innate and specific re-
ceptor levels. However, there is evidence that there is a systemic
inflammatory component to OA as well. In the current study, we
examined CD14+ peripheral blood monocytes from OA patients
for the expression of Toll-like receptors (TLR), TLR2 and TLR4,
and co-stimulatory molecules, CD80 and CD86, in order to de-
termine whether the cells from OA patients have increased levels
compared with normals. Monocytes from RA patients were also
compared.
Methods: Blood was collected 45 patients with OA, 45 patients
with RA, and 25 normals. TLR2 and TLR4 expression on CD14+
peripheral blood mononuclear cells (PBMCs) were measured by
flow cytometry using anti-CD14, anti-TLR2 and anti-TLR4 mono-
clonal antibodies. CD80 and CD86 expression on CD14+PBMCs
were also measured by flow cytometry using anti-CD14, anti-
CD80 and anti-CD86 monoclonal antibodies. Appropriate isotype
controls were used. Results are expressed as a ratio to control.
Results: Preliminary data suggest TLR2 expression (expressed
as a ratio to control) was significantly increased for OA patients
(p<0.05) and RA patients (p<0.05), compared with normals. For
OA monocytes, TLR4 expression (expressed as a ratio to control)
was no different to normals, whereas expression was decreased
on cells from RA patients (p<0.05). CD14highCD16+ monocytes
showed the greatest expression of TLR2 on both OA and RA
monocytes. The co-stimulatory molecules CD80 and CD86 were
not increased on OA monocytes, whereas CD86 was increased
on RA monocytes.
Conclusions: OA monocytes show some differences from nor-
mal monocytes, at least in TLR2 expression, suggesting perhaps
that aspects of the innate immune system may be involved in OA
pathogenesis.
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Purpose: To evaluate the sensitivity of a panel of biomarkers for
type II collagen turnover, alone or in combination, to differentiate
patients with radiographic and symptomatic osteoarthritis (OA)
from healthy controls that could be used to help monitor OA
disease progression and therapeutic intervention.
Methods: Levels of the urinary type II collagen degradation
biomarkers uCTX-II and uTIINE, and the blood type II collagen
synthesis biomarkers plNPII, sCPII and sPIIANP were measured
in 177 subjects aged > 40 years (mean = 57). Eighty-four
patients had symptomatic OA in at least one knee. The diagnosis
of symptomatic OA (SOA) was based on a combination of pain
or stiffness on most days of a month during the past year and
the presence of radiographic OA as defined by Kellgren and
Lawrence grades (KLG) 2 and 3. Ninety-three age- and sex-
matched healthy controls had no symptoms and a KLG = 0.
ELISA assays were used to measure uCTX-II, sPIIANP (Synarc,
France) and sCPII (IBEX, Canada). uTIINE was measured by
LC/MS/MS and plNPII was measured by a recently developed
competitive ELISA assay in-house. Statistical analyses were
performed on Log-transformed data.
Results: The mean (SD) levels of uCTXII, uTIINE, plNPII, sCPII
and sPIIANP, were 203.39 (119.8) ng/mmol Creat, 76.95 (48.89)
ng/mmol Creat, 3.48 (3.65) ng/mL, 402.43 (126.83) ng/mL and
902.97 (669.55) ng/mL, respectively. The uCTXII and uTIINE
levels were significantly larger in OA patients compared to control
subjects (P-value <0.001). In contrast, the plNPII levels were
significantly smaller in OA patients compared to control subjects
(P-value = 0.04). Both sCPII and sPIIANP levels were similar
in both groups (P-value = 0.52 and 0.27, respectively). Levels
of both degradation markers uCTX-II and uTIINE were well
correlated (R = 0.64, p < 0.0001). Among the synthesis markers,
